Exelixis Inc. (NASDAQ:EXEL) appoints Dana T. Aftab as Executive Vice President, Research & Development. Dr. Aftab has been with the company for over 25 years and played a key role in developing CABOMETYX, a leading drug for treating advanced cancers. This appointment follows the departure of Amy Peterson, M.D.

Exelixis Inc. (NASDAQ:EXEL) is an oncology company focused on developing medicines for challenging cancers in the US. While EXEL shows potential, some AI stocks may offer better returns with less risk. For more information on undervalued AI stocks, refer to Insider Monkey’s free report on the best short-term AI stock.

For more investment opportunities, check out Insider Monkey’s articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. This article is published on Insider Monkey’s website.

Read more at Yahoo Finance: Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D